NORDIC NANOVECTOR ASA – SALE OF SHARES BY MANAGEMENT MEMBER


Jostein Dahle, who is the Chief Scientific Officer of Nordic Nanovector ASA (the “Company”), has on 20 January 2015 sold 4,000 shares in the Company at a price of NOK 32 per share. Following the share sale, Mr Dahle holds 264,358 shares in the Company.

The shares were sold to finance the purchase price and strike price for shares already acquired, and tax relating to share acquisitions and sales.

Luigi Costa, CEO
Cell:    (41) 79 124 8601 
Fax:    (47) 22 58 00 07
E-mail: lcosta@nordicnanovector.com

Tone Kvåle, CFO
Cell:    (47) 91 51 95 76
Fax:    (47) 22 58 00 07
E-mail: tkvale@nordicnanovector.com

About Nordic Nanovector ASA (ticker: NANO on NOTC)

Nordic Nanovector ASA is a privately held company established in 2009. The company is developing innovative radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other difficult to treat cancers. Nordic Nanovector intends to commercialise its product candidates through strategic alliances and partnerships with experienced oncology businesses and by establishing its own sales and marketing capabilities in selected markets. The company is based and has offices and laboratories in Oslo, Norway.

The company’s lead product candidate, Betalutin™, is a radioimmunotherapeutic that aims to prolong and improve the quality of life of people who suffer from NHL. Further information can be found at: www.nordicnanovector.com .

Tags:

About Us

About Nordic Nanovector ASA Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.Further information about the Company can be found at www.nordicnanovector.com

Subscribe

Media

Media